What type of study is this?

December 8, 2025BloodOpen Access

Transfusion independence in thalassemia patients after failure of gene therapy or with hemoglobin h constant spring and hb e using luspatercept: A case series

View Full Paper

Ask AI

Bookmark

Authors

Case series reports that luspatercept enhances hemoglobin and reduces transfusion needs in thalassemia, suggesting a potential new therapy option.

Hemoglobin levels stabilized above 10 g/dL in two thalassemia patients using luspatercept.
Luspatercept led to transfusion independence for over 2 years in patients previously reliant on transfusions.
Analysis focused on responses to luspatercept after gene therapy failure and in alpha thalassemia cases.
Findings indicate luspatercept may provide long-term benefits for transfusion-dependent thalassemia populations.

Chandler et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Case series reports that luspatercept enhances hemoglobin and reduces transfusion needs in thalassemia, suggesting a potential new therapy option.

Hemoglobin levels stabilized above 10 g/dL in two thalassemia patients using luspatercept.
Luspatercept led to transfusion independence for over 2 years in patients previously reliant on transfusions.
Analysis focused on responses to luspatercept after gene therapy failure and in alpha thalassemia cases.
Findings indicate luspatercept may provide long-term benefits for transfusion-dependent thalassemia populations.

Chandler et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark